Effect of esomeprazole 40 mg vs omeprazole 40 mg on 24-hour intragastric pH in patients with symptoms of gastroesophageal reflux disease

被引:121
作者
Röhss, K
Hasselgren, G
Hedenström, H
机构
[1] AstraZeneca R&D, S-43183 Molndal, Sweden
[2] Univ Hosp, Dept Med Sci, Uppsala, Sweden
关键词
esomeprazole; omeprazole; gastroesophageal reflux disease; intragastric pH; pharmacodynamics;
D O I
10.1023/A:1015009300955
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Maintenance of intragastric pH > 4 is vital for effective management of gastroesophageal reflux disease (GERD). Esomeprazole 40 mg, the first proton pump inhibitor developed as an optical isomer, demonstrates improved acid inhibition over omeprazole 210 mg. Our aim was to compare esomeprazole 40 mg with omeprazole 40 mg, once-daily, on intragastric acidity in patients with symptoms of GERD. In this open-label, crossover study, 130 patients with symptoms of GERD received esomeprazole 40 mg or omeprazole 40 mg once-daily for five days. The 24-hr intragastric pH was monitored on days 1 and 5 of each treatment period. The mean percentage of the 24-hr period with intragastric pH > 4 was significantly greater (P < 0.001) with esomeprazole 40 mg than with omeprazole 40 mg on days 1 (48.6%, vs 40.6%) and 5 (68.4% vs 62.0%). Interpatient variability was significantly less with esomeprazole than omeprazole. Esomeprazole was well tolerated. In conclusion, esomeprazole 40 mg provides more effective acid control than twice the standard dose of omeprazole.
引用
收藏
页码:954 / 958
页数:5
相关论文
共 18 条
  • [1] APPROPRIATE ACID SUPPRESSION FOR THE MANAGEMENT OF GASTROESOPHAGEAL REFLUX DISEASE
    BELL, NJV
    BURGET, D
    HOWDEN, CW
    WILKINSON, J
    HUNT, RH
    [J]. DIGESTION, 1992, 51 : 59 - 67
  • [2] Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: A meta-analysis
    Chiba, N
    DeGara, CJ
    Wilkinson, JM
    Hunt, RH
    [J]. GASTROENTEROLOGY, 1997, 112 (06) : 1798 - 1810
  • [3] Crawley J.A., 2000, J CLIN OUTCOMES MANA, V7, P29
  • [4] An evidence-based appraisal of reflux disease management - the Genval workshop report
    Dent, J
    Brun, J
    Fendrick, AM
    Fennerty, MB
    Janssens, J
    Kahrilas, PJ
    Lauritsen, K
    Reynolds, JC
    Shaw, M
    Talley, NJ
    [J]. GUT, 1999, 44 : S1 - S16
  • [5] DeVault KR, 1999, AM J GASTROENTEROL, V94, P1434
  • [6] GASTRIC-ACIDITY AND GASTROESOPHAGEAL REFLUX PATTERNS IN PATIENTS WITH ESOPHAGITIS
    FIORUCCI, S
    SANTUCCI, L
    CHIUCCHIU, S
    MORELLI, A
    [J]. GASTROENTEROLOGY, 1992, 103 (03) : 855 - 861
  • [7] Heartburn, treatment in primary care: randomised, double blind study for 8 weeks
    Hatlebakk, JG
    Hyggen, A
    Madsen, PH
    Walle, PO
    Schulz, T
    Mowinckel, P
    Bernklev, T
    Berstad, A
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 1999, 319 (7209): : 550 - 553
  • [8] HEARTBURN - THE ACID TEST
    JOELSSON, B
    JOHNSSON, F
    [J]. GUT, 1989, 30 (11) : 1523 - 1525
  • [9] DEVELOPMENT OF THE 24-HOUR INTRAESOPHAGEAL PH MONITORING COMPOSITE SCORING SYSTEM
    JOHNSON, LF
    DEMEESTER, TR
    [J]. JOURNAL OF CLINICAL GASTROENTEROLOGY, 1986, 8 : 52 - 58
  • [10] Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial
    Kahrilas, PJ
    Falk, GW
    Johnson, DA
    Schmitt, C
    Collins, DW
    Whipple, J
    D'Amico, D
    Hamelin, B
    Joelsson, B
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2000, 14 (10) : 1249 - 1258